Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we established a new tumour model which closely resembles the situation in patients who receive androge...
Shranjeno v:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | angleščina |
| Izdano: |
1999
|
| Online dostop: | https://doi.org/10.1038/sj.bjc.6690684 https://www.nature.com/articles/6690684.pdf |
| Oznake: |
Označite
Brez oznak, prvi označite!
|